Vaccine

Video related to the published article in Vaccine: James E. Moon et al. 2021 DOI: 10.1016/j.vaccine.2021.09.024 Clinical Trial Registration: NCT03824236

Supplementary dat a of a cost effectiveness analysis of a potential hexavalent CPS-protein conjugate vaccine in the GAmbia. Further data to follow.

baseline control and intervention is the baseline results of studnets. post education is the results of studnets who receive intervention immediately. one year follow up both control and intervention is the results of studnets at one year later.

Vivax malaria is a major cause of morbidity and mortality worldwide, with several million clinical cases per year and 2.5 billion at risk of infection. A vaccine is urgently needed but the most advanced malaria vaccine, VMP001, confers only very low levels of protection against vivax malaria challenge in humans. VMP001 is based on the circumsporozoite protein (CSP) of Plasmodium vivax. Here a virus-like particle, Qβ, is used as a platform to generate very high levels of antibody against peptides from PvCSP in mice, in order to answer questions important to further development of P. vivax CSP (PvCSP) vaccines. Minimal peptides from the VK210 and VK247 allelic variants of PvCSP are found to be highly protective as Qβ-peptide vaccines, using transgenic P. berghei parasites expressing the homologous PvCSP allelic variant. A target of neutralising antibodies within the nonamer unit repeat of VK210, AGDR, is found, as a Qβ-peptide vaccine, to provide partial protection against malaria challenge, and enhances protective efficacy when combined with full-length PvCSP vaccination. A truncated form of PvCSP, missing the N-terminal domain, is found to confer much higher levels of protective efficacy than full-length PvCSP. Peptides derived from highly conserved areas of PvCSP, RI and RII, are found not to confer protective efficacy as Qβ-peptide vaccines.

1. ELISAS of immunological assessment 2. Antigenic characterization

Raw data for figures in manuscript

Content analyses of public HPV vaccine related Facebook posts.

This is the first systematic evaluation that simultaneously confirm egg allergy through recommended gold standard tests and proceed yellow fever administration with a safe protocol in egg-allergic patients. Therefore, we withdraw from the research patients who were already tolerant to egg protein and those who were never actually allergic. We also described the intensity of patient’s allergy at the time of vaccination.

Raw data from ELISA, ELISPOT, FACS, and neutralization assays

1) ABC_submitter_instructions.txt- How to use ABCpred_submitter.py/required packages for ABCpred_submitter.py 2) ABCpred_submitter.py- Submits FASTA sequences to ABCpred server. Writes an output file of ABCpred epitopes 3) 117_M_types.txt- The 117 M types in this study. Input for the ABCpred_submitter.py. 4) ABCpred_16mer_epitopes.txt- The 16 residue linear B-cell epitopes for the 117 M types in this study. Output for the ABCpred_submitter.py.